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CHARACTERIZATION OF A MICRORNA HARBORING INTRON FOR PREMRNA SPLICING AND MICRORNA PROCESSING

NEHA AGGARWAL
ABSTRACT

Nuclear pre-mRNA splicing is an important step in eukaryotic RNA processing
and can yield a variety of transcripts. Further, it is known that nuclear pre-mRNA introns
are of two types, U2-dependent and U12-dependent. Recently discovered, microRNAs
(miRNA) are short, endogenous, 20-22 nucleotide long, non-coding RNA molecules that
base pair with target mRNAs to modulate translation. Current evidence suggests that
processing of intronic miRNA does not affect the splicing. Since, intronic miRNAs are
involved in essential cellular processes, we surmised if splice sites of miRNA coding
introns are flexible to support productive precursor and mature miRNA processing.
We constructed a minigene reporter consisting exons 26-29 including introns
from MYH6 gene and an intronic miRNA, miR-208 harbored in intron 27. Using in vivo
and in vitro methods, we examined splicing of MYH6 intron 27 and processing of miR208. The predicted stem-loop structure of miR-208 and the 5’ splice site of the intron 27
were mutated. Stem-loop mutations had no recordable splicing defect of intron 27. The
5’SS mutant activated a cryptic splicing event using a sub-optimal splice site located 50
nucleotides upstream of wild-type splice site. Interestingly, conversion of U2-type 5'
splice site to consensus U12-type 5' splice site did not affect in vivo splicing of the intron,
suggesting potential conversion of intron to U12-type, albeit without a consensus U12-
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type branch site sequence. However, miRNA processing was affected as established by in
vitro splicing assay and qRT-PCR analysis of miR-208.
We mutated nucleotides from position 3 to 7 in intron 27 to study if changes in
splice site will allow miRNA processing to occur and if splicing will also be affected.
Our data indicates significant changes in spliced phenotype as well as in miR-208
expression level.
Since, all known intronic miRNAs are harbored in U2-dependent introns of
mammalian genes, we wanted to study if miRNA processing will be compatible with
U12-dependent intron. With this aim, we incorporated miR-208 in a U12-dependent
intron. However, it appears that spliceosome and microprocessor cannot act together in a
U12-dependent intron. This is first time that a miRNA has been incorporated in a U12dependent intron to study its processing and also if splice sites are plastic for miRNA
processing.
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CHAPTER I
INTRODUCTION

1.1 Gene Expression
The “central dogma” of developmental biology holds that growth and development
is governed by regulated changes in gene expression. Gene expression involves
transcription of DNA (genes) to RNA and then translation from RNA to proteins that
directly affect cellular functions. Both transcription and translation processes are the basic
fundamentals of molecular biology and both processes are strictly regulated at various steps
(Hartwell et al, 2004). This regulation at different levels and stages in a cell leads to a
differential expression and hence to different cell and tissue types.
Gene expression is influenced by a number of cellular processes, such as
transcriptional regulation, RNA processing, compartmentalization, translational regulation
etc (Figure 1). Each eukaryotic gene has its own promoter and its transcription is regulated
by transcriptional activators or transcription factors. Eukaryotic genes also have one or
more enhancers generally upstream of the promoter. The promoter is responsible for
initiating low levels of transcription and determining the transcription start site, enhancers
are responsible for increasing ("enhancing") transcription levels, and they are also
responsible for regulating cell or tissue-specific transcription.aaaaaaaaaaaaaaaaaaaaaaaaaaa
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For example, human β globin gene cluster consists of 5 functionally active genes (ε,
Gγ, Aγ, δ and β genes) expressing at different stages of life, from embryonic to adulthood
(Li et al, 1990). It has a ~12 kb enhancer region with binding sites for GATA-1, NF-E2,
AP-1 and some other transcriptional activators. GATA-1 binds at embryonic stage
(Takahashi et al, 1997), preferentially expressing the ε gene. In fetal DNA, Gγ and Aγ are
more strongly expressed and in adults, expression is switched to β gene, while the δ gene is
weakly expressed (Li et al, 2002).
Histone regulation and chromatin remodeling are also involved in regulation of
transcription. Chromatin is condensed to inactive form- heterochromatin. Covalent
modification such as methylations, acetylations, deacetylations etc of histones occurs,
reducing transcription. Histone Acetyltransferases (HATs) acetylates lysine residues in
histone proteins, leads to chromatin remodeling as well as making DNA accessible for
transcription (Grunstein, 1997).
Most of the gene-expression changes which are involved in development are
associated with changes in the level of mRNAs and their regulation (Figure 1). RNA
polymerase II (RNA pol II) transcribes majority of protein-coding genes. The pre-mRNA
synthesized by RNA pol II is processed before it can be translated. RNA processing
involves 5’ capping, 3’ modification by addition of a 3' poly (A) tail, and intron splicing
(Proudfoot et al, 2002; Shatkin and Manley, 2000; Staley and Guthrie, 1998). If pre-mRNA
is capped and polyadenylated, it would be transported to the cytoplasm for translation
otherwise it would be retained in the nucleus for degradation. Introns are spliced in the
nucleus by formation of a series of dynamic complexes governing introns to be spliced
(Moore et al, 1993). This process of splicing affects the function of the protein produced.
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Some genes have exons that might be spliced, producing a different transcript and a
functionally different protein for example; the calcitonin gene produces calcitonin hormone
in parafollicular cells of thyroid (Copp and Cheney, 1962; Hirsch et al, 1963) and a
neurotransmitter (CGRP) in neurons (Brian et al, 1985). This process is called alternative
splicing and is now known to be involved in a number of diseases.
mRNAs from different genes have their approximate lifespan encoded in them. The
information for lifespan is found in the 3' UTR. The sequence AUUUA, when found in the
3' UTR, is a signal for early degradation and hence a short lifetime (Chen et al, 2001). The
more times this sequence is
present,

the

shorter

the

lifespan of the mRNA.
mRNA

is

also

regulated at translational level.
Translation in eukaryotes is
divided into three stages (i)
initiation

(governed

by

initiation factors, eIFs), (ii)
Figure 1: Levels of gene
expression control:
Gene expression is
regulated at various steps
during transcription as
well as translational
processes.
elongation

(governed

by

elongation factors, eEFs) and
3

(iii) termination (governed by release factors). Translational regulation is exerted mostly at
the first stage i.e. initiation, where the AUG start codon (sometimes GUG) is identified. It
is generally regulated by eIF2 or eIF4.
Recently, it has been shown that RNA pol II is involved in transcription of
microRNAs, a novel class of small RNA molecules regulating translation (discussed in
detail in section 2.3). These are small RNAs which modulate translation, mRNA
degradation and perhaps other processes. Depending upon complementarily of miRNA
with the 3’UTR of mRNA transcript, mRNA transcript is either degraded or translation is
inhibited.

1.2 Nuclear Precursor mRNA (pre-mRNA) Splicing
Pre-mRNA splicing involves removal of intervening introns and joining of exons
forming a mature mRNA. This process appears to occur co-transcriptionally and is an
essential step in RNA processing. When “interrupted” gene produces primary transcription
product a heterogeneous nuclear RNA molecule (pre-mRNA), both exons and introns are
represented. Introns, however, are removed from the primary transcript during the
processing of pre- mRNA in specific splicing reactions. Splicing is usually constitutive,
which means that all exons are joined together in the order in which they occur in the
heterogeneous nuclear RNA (Sharp, 1985). In many genes, however, alternative splicing
has also been observed, in which exons may be combined in some other way. It is a process
by which certain exons are skipped and hence the mature mRNA formed is different. This
leads to formation of different proteins. Alternative splicing is another mechanism by
which a high degree of diversity and variance can be achieved. Alternative splicing is an
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important aspect of gene regulation and about 75% of human genes encode pre-mRNAs
that are alternatively spliced. Numerous diseases are associated with alternative splicing
and splicing isoforms. Additionally, the proteins encoded by alternative isoforms of a
particular gene have distinct biological functions (Black, 2003).

1.2.1 Intron: Types, Sequence Conservation and Splicing
After the discovery of split genes in 1977, conserved sequences at both ends of
introns were recognized. These sites are called 5’ splice site and 3’ splice site respectively.
Another conserved sequence called the branch point region is located within the intron. It is
usually 20–40 nucleotides upstream of the 3’ splice site. The branch point is almost always
an adenosine and can rarely be guanine. The sequences at intron ends were GT at the 5’
splice site and AG at the 3’ splice site and led to formulation of GT-AG rule (Breathnach et
al, 1978). This rule holds true in most cases but a number of exceptions to this have been
found. For example, GC is found at 5’ splice site in case of intron 7 of Human laminin α-4
(LAMA4) gene (Richards et al, 1997). After about 10 years, it was found that intron F of
the gene encoding human P120, a proliferating cell nucleolar antigen, and intron 7 of the
gene encoding human CMP, a cartilage matrix protein have AT and AC at the 5’ and 3’
intron ends respectively, instead of GT and AG (Jackson, 1991). Later on, intron 6 of the
gene encoding Rep-3, a DNA repair protein, and intron 2 of the gene encoding Prospero, a
Drosophila melanogaster homeodomain transcription factor were shown to have AT-AC
ends (Hall and Padgett, 1994). It was also shown that AT-AC introns have highly
conserved 5’ splice site and presumptive branch site sequence elements that are not present
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in the GT-AC introns, namely, ATATCCTY and CCTTRAY, respectively (Hall and
Padgett, 1994).
The splice sites and branch point region interact with specific RNA and protein
factors to engage the spliceosome. The spliceosome is formed by small nuclear RNAs
(snRNAs) and a number of protein constituents called ribonuclear proteins (RNPs).
snRNAs and RNPs are together called snRNPs (or snurps). Spliceosome is a dynamic
complex structure which undergoes rearrangements and finally leading to catalysis
(Konarska and Sharp, 1987).

Major (U2-dependent)

Minor (U12-dependent)

Spliceosome

Spliceosome

U1

U11

U2

U12

U4

U4atac

U5

U5

U6

U6atac
Table 1: snRNAs involved in Splicing

Depending on the conserved sequences in an intron, two spliceosomal systems are
known to exist in a eukaryotic system. Both the systems recognize 5’splice site, branch
point sequence and 3’ splice site flanking the intron in a gene. However, the conserved
consensus sequences recognized are different. But the chemistry involved in splicing
through both pathways is same. Majority of introns are spliced by U2-dependent pathway

6

(major pathway) involving U1, U2, U4, U5 and U6 snRNAs (Table 1) (Tycowski et al,
2006). Generally GT-AC introns and GC-AG introns are splices by major pathway
however, some exceptions exist (Dietrich et al, 1997). AT-AC introns are spliced by the
U12-dependent pathway (minor pathway) involving U11, U12, U4atac, U5 and U6atac
snRNAs (Table 1) (Hall and Padgett, 1996; Tarn and Steitz, 1996 a, b).

1.2.2 Process of Splicing
Splicing occurs by formation of a large spliceosomal complex and involves two
trans-esterification reactions. The splicing mechanism involves 2 steps: (i) cleavage of the
5′ exon–intron phosphodiester bond and formation of a new 2′–5′ bond resulting in an
intron lariat and (ii) exon ligation. In the first step, the branch point adenosine attacks the 5’
splice

site,

phosphodiester

breaking

the

bond

and

Figure 2: Mechanism of
RNA splicing: Step 1 shows
the nucleophilic attack of
branch point Adenosine on
phosphate of 5’ exon. Second
step shows the attack of 5’
exon at 3’ exon bound to
lariat intermediate and finally
the formation of lariat
intermediate and spliced
exons (Sperling et al, 2008)

Step 1

Step 2

simultaneously forming a 2’-5’
phosphodiester linkage between the branch point and the 5’ terminal nucleotide of the
intron. The products of the first reaction are free 5’ exon and 3’ exon bound to lariat intron.
7

After a conformational change within the spliceosome, the second step takes place. Here,
the newly released 3’ hydroxyl of the 5’ exon, created by the first step, attacks the 3’ splice
junction, breaking that phosphodiester bond while forming a new phosphodiester bond
between the 5’exon and 3’ exon (Sperling et al, 2008). The products of the second step are
ligated exons and the free
intron, released in the form
of a lariat intermediate
(Figure 2). These reactions
involve rearrangement of
snRNPs and formation of
spliceosome.
Spliceosome
formation is a complex
process in which snRNAs
and protein components of
snRNPs are sequentially
loaded on the intron to be
spliced (Nilsen, TW, 1998;
Will and Luhrmann, 2001,
2006). E complex is the
Figure 3: Major and minor spliceosomal pathways:
Consensus 5’ splice site, branch site and 3’ splice site are
shown for U2 and U12-dependent introns in the upper
panel. The formation of splicing complexes at various
stages during the process of splicing are shown in the
lower panel (Will and Luhrman, 2005).
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first to be formed when U1
binds to the GU sequence
at the 5' splice site (Zhuang

and Weiner, 1986), along with accessory proteins/enzymes such as U2AF (Figure 3). In
next step, U2 binds to the branch site; this is called the A Complex (Wu and Manley,
1989). A stable association of U2 snRNA with branch site requires ATP to form the
prespliceosome. B complex is formed following A complex, by the binding of U5/U4/U6
tri-snRNP (Konarska and Sharp, 1987). The U5 snRNA binds exons at the 5' splice site and
U6 snRNA binds to U2 with release of U1 snRNA. Then, U5 shifts from exon to intron and
U6 binds at the 5' splice site by RNA: RNA interactions (Madhani and Guthrie, 1994). For
the C complex formation, U6 and U2 catalyze trans-esterification reaction and U4 is
released from the complex (Lewis and Seraphin, 1993). In next step, with U2, U5 and U6
still bound, exons are spliced (Nilsen, 1998; Staley and Guthrie, 1998). The final products
after splicing are spliced exons and lariat intron. Snurps are recycled again used for the
next round of splicing (Moore et al, 1993).
snRNAs involved in U12-dependent pathway are functional analogs of their U2
dependent counterparts. U11 is a functional analogue of U1 snRNA, U12 of U2, U4atac of
U4 and U6atac of U6. U5 snRNA is common to both the pathways. There are a few
differences in splicing by minor spliceosomal pathway (Figure 3). In case of minor
pathway, U11/U12 di-snRNP is formed and binds to 5’ splice site and branchpoint
adenosine resulting in formation of A complex. U4atac/U5/U6atac tri-snRNP then binds
the intron forming B complex (Tarn and Steitz, 1996(b)). Transesterification reactions for
U12-dependent pathway are similar to U2-dependent pathway (Nilsen, 1996).
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1.2.3 Methods to Study pre-mRNA Splicing
Pre-mRNA splicing is generally studied by two approaches, in vivo and in vitro
methods. These studies have demonstrated the roles of sequence elements in the premRNA and the snRNAs in various interactions and the stepwise assembly of the
spliceosome. The in vivo approach involves transient transfection of wild-type or mutant
minigenes and then analyzing the spliced variants by RT-PCR method. For in vivo studies,
a suppressor system is developed in which few mutations are introduced in minigene and
compensatory base changes in snRNAs are made, allowing minigene to splice as good as
wild type. It is known that the 5’ end of U1 snRNA and the intronic 5’ splice site interact
via base pairing (Zhuang and Weiner, 1986; Siliciano and Guthrie, 1988). For major
pathway, a compensatory base change in U1 snRNA can suppress 5’ splice site mutation
(Zhuang and Weiner, 1986), allowing splicing to occur as wild type. In case of AT-AC premRNA splicing (minor splicing), suppressor assay system has also been established. In an
AT-AC intron, it has been shown that CC at 5th and 6th position in the conserved 5’ splice
site sequence, ATATCCTY, are absolutely necessary for splicing to occur by the U12dependent pathway (Hall and Padgett, 1996; Kolossova and Padgett, 1997; Incorvaia and
Padgett, 1998). Suppressor AT-AC snRNAs can be cotransfected with AT-AC intron
mutants to study base pairing interactions between intron and snRNAs.
An in vitro splicing method involves splicing of a pre-mRNA transcript in presence
of nuclear extract. In an in vitro transcribed mRNA transcript is called substrate which
upon in vitro splicing reaction leads to formation of free lariat intermediate, spliced exons,
free 5’ exon, lariat intermediate with 3’ exon and all these products can be detected on the
gel. The in vitro systems for AT-AC pre-mRNA splicing make possible to study the
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biochemical mechanisms of the reaction. In vitro splicing of has been established for both
U2-dependent pathway (Moore et al, 1993) and U12-dependent pathway (Tarn and Steitz,
1996 a). Model minigene system for U2-dependent pathway is human adenovirus-2 gene
and for U12-dependent pathway is intron F of p120 gene. Both U2-dependent and U12dependent splicing occurs in two steps involving trans-esterification reactions and the
results for splicing are similar in both in vitro splicing systems.
Both in vivo and in vitro methods have certain advantages and disadvantages.
Almost every construct transfected in cells splices upon transfection in contrast to in vitro
splicing methods where the splicing ability is limited. Utilizing the in vivo system, different
cell lines can be tested. However, in vivo splicing is prone to indirect effects since intact
cells are used. Using the in vitro approach, we can differentiate whether splicing occurs by
major (U2-dependent) or minor pathway (U12-dependent) by blocking one or more
snRNAs. This inactivation of snRNAs is achieved using 2’O-methyl oligos. For blocking
U2-dependent splicing, inactivation of U2 snRNAs in the nuclear extract is required to
detect splicing. However, inactivation of U2 snRNA in addition to U12 snRNA is required
to block the U12-dependent splicing (Tarn and Steitz, 1996 a). It is believed that since, U2
is about a hundred times more abundant than U12, U2 competes with U12 for binding to
the AT-AC branch site (Montzka and Steitz, 1988). Another advantage of the in vitro
system is enabling to study the kinetics of splicing reaction since an in vitro reaction can be
stopped at different time points and studied for complex formation. Also different snRNAs
can be blocked (using 2’O-methyl oligo) and intermediate products can be studied, giving
insight on the process.
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1.3 MicroRNAs
MicroRNAs (miRNAs) are short, endogenous, 20-22 nucleotide long, non-coding
RNA molecules that can regulate gene expression by base pairing with target mRNAs (Lee
et al, 1993; Lee and Ambros, 2001; Lagos-Quintana et al, 2001; Kim, 2005; Kim and Nam,
2006). The founding microRNA lin-4 was discovered more than 25 years ago in the
nematode Caenorhabditis elegans (Lee et al, 1993). Large numbers of miRNAs have been
identified since then, making it one of the largest growing fields in the RNA world. To
date, more than 10884 mature miRNAs have been annotated and 721 of these are human
microRNAs. They are known to exist in 115 different species, from viruses, fungi to plants
and

vertebrates

(mirBase,

14th

release;

Griffiths-Jones,

2008).

MiRNAs

are

computationally found across the genome and then they are confirmed experimentally by
cloning (Bentwich, 2005). Targets for some of miRNAs are also found computaionally first
and later on confirmed experimentally (Bentwich, 2005). Many miRNAs are conserved
across the species indiacting their evolutionary significance. MiRNAs are known to have
important functions in cellular biology for example; miR 134 is involved in embryonic
stem cell differentiation (Tay et al, 2008), miR 17-92 cluster in adipogenesis (Wang et al,
2008) and in cell proliferation and cancer as well (Hayashita et al, 2005). miRNA
involvement is also implicated in a number of diseases such as, miR 9 and miR 223 for
ovarian cancer (Laios et al, 2008), miR 375 for Diabetes (Poy et al, 2004, 2009).

1.3.1 miRNA Biogenesis
MiRNA biogenesis refers to the processing microRNA from primary transcript to
mature form (Figure 4). Majority of miRNAs are transcribed by RNA polymerase II
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(Cullen et al, 2004; Lee et al, 2004; Lee et al, 2002) and some through RNA polymerase III
(Borchert et al, 2006). The transcript formed is called as primary miRNA and has a stemloop structure of about 125 nucleotides. These are processed in a number of steps in both,
nucleus and cytoplasm to yield
mature miRNA. In nucleus, primiRNA is excised by Drosha,
an RNase III-type enzyme (Lee
et al, 2003). Drosha functions as
a large protein complex called
Microprocessor complex that
contains DGCR8/Pasha as well
as

several

splicing

factors.

Cleavage of pri-miRNAs by the
microprocessor

complex

(Drosha)

in

results

the

production of shorter, stemloop-shaped

RNAs

called

Figure 4: miRNA biogenesis pathway: MiRNA genes are transcribed by RNA
polymerase II to generate the pri-miRNAs. The initial cropping step by the DroshaDGCR8 complex, results in formation of pre-miRNA (~70-nt), which is exported by
the Exp5-Ran complex. Upon export, Dicer participates in the second step of
processing to produce miRNA duplexes. The duplex is separated and one strand is
selected as mature miRNAs (http://www.euchromatin.com/ChenCZ01F1.jpg)

precursor miR (pre-miR). These RNAs are ~70 nucleotides long and are exported to the
cytoplasm by Exportin 5/Ran-GTP complex (Bohnsack et al, 2004; Yi et al, 2003). In the
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cytoplasm, pre-miRs are cleaved by the cytoplasmic RNase III-type enzyme, Dicer
(Ketting et al, 2001). The cleavage reaction yields short RNA duplexes and, subsequently
one strand of each duplex is incorporated into the RNA-induced silencing complex (RISC).
RISC complex delivers miRNA to its target mRNA through base pairing with the 3’
untranslated regions (UTR). If the miRNA is fully complementary to the 3’UTR of target
mRNA, it leads to mRNA degradation and if it has incomplete complementarity with
target, it induces translational repression.

1.3.2 Genomic Locations of miRNA
Based on genomic location relative to protein-coding gene locus, miRNA can be
divided into intergenic or intronic miRNAs. Intergenic miRNAs are found in region
between the two genes. They generally are independent transcription units, and have their
own promoters, transcript sequences and terminator sequences; such as lin-4 and let-7
miRNAs from C. elegans (Bartel, 2004; Kim, 2005). On the other hand, intronic miRNAs
are located in the introns of a protein-coding gene. They do not have their own promoters
but are transcribed from the promoter of the protein gene (Kim, 2005). Intronic miRNA is
similar to the intergenic miRNA, structurally and functionally; difference being in location
and requirement for RNA polymerase II for transcription for most intronic miRNAs (Cai et
al, 2004). However, RNA polymerase III has also been shown to transcribe miRNAs from
repetitive sequences where the human C19MC 5’ Alu function as miRNA promoters
(Borchert et al, 2006).
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1.3.3 Intronic miRNAs
Much is known about miRNA biogenesis and the post-transcriptional affects it has
on protein coding genes, but very less is known about the transcriptional regulation of
intronic miRNAs. Recently with advances in the field, it was found that about 80% of
miRNAs are encoded in the intronic regions of protein-encoding or non-coding genes in
mammals (Rodriguez et al, 2004; Kim and Kim, 2007) and 75% in Xenopus tropicalis
(Tang and Maxwell, 2008). This also indicates that the miRNA harbored in introns might
be evolutionarily conserved in vertebrates. It was earlier thought that all miRNAs have
their own promoter regions but the expression of intronic miRNAs largely coincides with
that of their host genes (Baskerville and Bartel, 2005). miRNAs are transcribed from their
host gene promoters and processed post-transcriptionally from the host pre-mRNAs
(Sikand et al, 2009). According to computational analysis miRNAs may regulate about
60% of protein encoding genes, suggesting some important, yet undiscovered regulatory
mechanisms.
The fact that mature mRNAs and intronic miRNAs are generated from same
transcript may have some unknown significance. It was shown that the miRNA-containing
intron is spliced out slower than the other introns (Kim and Kim, 2007) and a model was
proposed in which Drosha cleaves the pre-miRNA before the intron is spliced out and the
two RNA fragments, produced by the pre-miRNA cropping from the pre-mRNA, and
might subsequently be trans-spliced. Recently, Kataoka et al (2009), using in vitro splicing
assay system have shown that pre-miRNA cropping could occur prior to mRNA splicing.
Moreover, the presence of miRNA in the intron slowed splicing while increasing premiRNA production. They have also shown a Y-shaped intermediate and a Y shaped intron
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indicating trans-splicing. Recently, the association of Drosha (microprocessor) and
spliceosomal snRNPs has been shown using northern blotting analysis (Kataoka et al,
2009). This indicates there is a cross-talk between the spliceosomal machinery and the
micro processor which leads to processing if miRNA from the intron as well as splicing of
the pre-mRNA.

1.4 Model System: Myosin Heavy Chain and miR 208
Myosin heavy chain (MHC or MYH) genes are expressed in the heart and largely
regulate cardiac contractility. MHC gene has two isoforms, α and β, which are regulated
developmentally. β-MHC (MYH7), is the dominant isoform expressed in the embryonic
heart and slow skeletal muscle whereas α- MHC (MYH 6) is expressed postnatally in the
heart (Weiss and Leinwand, 1996). Thyroid hormone (T3) signaling stimulates α-MHC and

Figure 5: Representation of MYH6 gene and miR-208: Shown is the location of
miR-208 in intron 27 of MYH6 gene which is a 24.63 kb long gene. Asterisks show
the sequence conservation across humans, mouse, rat and dog. Also depicted is the
proposed stem-loop structure of miR-208 and mature miR-208 (vanRooij et al, 2007)
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inhibits β-MHC transcription after birth (Morkin, 2000). However, in state of heart disease
there is a switch in MHC genes from α (fast contracting myosin) to β-MHC (slow,
embryonic myosin).
Human α- MHC (MYH 6) gene is 25.63 kb long and has 37 exons. Intron 27 of the
gene contains a highly conserved miRNA, miR-208a (Figure 5). MYH7 gene is a 23.8 Kb
long gene having 41 exons and intron 31 harboring miR-208b. miR-208a (referred as miR208) and miR-208b are 90% identical sequentially. The sequence alignment of miR-208 a
stem-loop, proposed stem-loop structure of miR-208 and mature miR-208 sequence are
shown in Figure 5. miR-208 stem-loop sequence is 90% identical across four species,
namely human, mouse, rat and dog, and the mature sequence is completely conserved. This

Figure 6: Regulation of cardiac contractility by miR-208: miR-208 expressed by
MYH6 negatively regulates THRAP1 expression. miR-208 absence results in
upregulation of skeletal muscle genes and hence cardiac hypertrophy (vanRooij et al,
2008).
indicates that miR-208 plays some important functions in heart. miR-208 plays an
important role in the regulation of β to α switch, cardiac hypertrophy and fibrosis. Mice
with homozygous deletion of mir-208 are viable but do not upregulate MYH7 expression in
17

response to cardiac stress; however other stress responsive genes were induced. This
indicated the role of this tiny miRNA in specifically controlling MYH7 expression.
miR-208 has a half-life of 14 days and therefore can exert its effects even in the
absence of MYH6 mRNA expression. miR-208 knockout mice at 2 months of age showed
expression of skeletal muscle contractile protein genes which otherwise are not expressed
in the heart. This indicated that miR-208 is expressed with MYH6 to repress the expression
of skeletal muscle genes in the heart (vanRooij et al, 2007).
MYH7 expression is repressed by thyroid hormone signaling and is
upregulated in hypothyroid state. Hypothyroidism can also be induced by treating mice
with thyroid hormone inhibitor, propylthiouracil. miR-208 knockout mice treated with
propylthiouracil were found to be resistant to MYH7 expression upregulation. Thyroid
hormone receptor (TR) coregulator TR-associated protein 1 (THRAP1) is the strongest
predicted target of miR-208 which can exert both positive and negative effects on
transcription (vanRooij et al, 2008). The TR represses MYH7 expression in the adult heart
through a negative thyroid hormone responsive element. In the absence of miR-208,
THRAP1 expression increases and hence would repress the MYH7 expression (Figure 6).
Knowing these facts about miR-208, we were interested in knowing if the miRNA
processing from the intron and splicing of pre-mRNA are related. Kataoka et al (2009)
have shown that the processing of miR-330 from intron of EML2 gene occurs prior to
splicing in vitro and both processes are coupled. If this is true universally, miR-208 is also
an intronic miRNA; hence it’s processing from the must be coupled to the process of
splicing. Another question to be answered is miRNA processing dependent on splice sites.
If the processes of miRNA processing and pre-mRNA splicing are coupled and trans-
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splicing occurs (Kataoka et al, 2009), miR processing could be related to 5’ splice site, 3’
site and conserved branch site sequences. Trans-splicing is a common phenomenon in
nematodes (Nilsen, 1993) and trypanosomes (Sutton and Boothroyd, 1986). Trans-splicing
has been established in vitro system as well and essentially involves the transfer of a 5'
exon from a pre-mRNA sequence containing an exon, 5’ splice site and adjacent intron to a
pre-mRNA transcript with exon, 3' splice site and adjacent intron (Konaraska et al, 1985).
For introns harboring miRNAs trans-splicing has been predicted, and after the processing
of miRNA from intron, trans-splicing takes place, hence the splice sites of the intron must
play an important role in the process. If this is true and splice sites play an important role,
how flexible or how permissive could the splice sites be to allow miRNA processing and
pre-mRNA splicing to occur.
Nearly 97% of the human genome is non-coding DNA and the intron occupies most
of it. Numerous intronic sequences have been recently found to encode microRNAs
(miRNAs), responsible for miRNA-mediated gene silencing (Ying and Lin, 2009). Several
kinds of intronic miRNAs have been identified in C. elegans, mouse, and human cells.
However, their functions and applications are not clear yet. Till date, intronic miRNAs are
known to exist only in U2-dependent introns only. This could possibly be due to the
requirement of RNA polymerase II and spliceosomal components for their biogenesis
(Ying et al, 2010). An interesting question arises, why is a miRNA not present in a U12dependent intron. Is minor spliceosome not compatible with miRNA processing. If a
miRNA is incorporated in a U12-dependent intron, will it be processed and pre-mRNA
splicing will also occur. Recently, it was shown that revealed that part of the pre-miRNA
cofractionated with the spliceosome in glycerol gradient sedimentation experiments
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(Kataoka et al, 2009. U2, U5, and U6 but not U1 or U4 snRNAs coprecipitated with
Drosha suggesting that major spliceosome associates with Drosha (microprocessor).
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CHAPTER II
MATERIALS AND METHODS

2.1 Minigene Construction
A genomic fragment of α-MHC gene consisting exons 26 through 29 was
amplified by PCR using primers MYH Xho F 5’-GCCTCGAGGAGAGTTGGCCCG
GCAG-3’ (forward) and MYH BamH1 R 5’-ACGGGATCCCCTGAAGGTTCTTGTTC3’ (reverse). The amplified fragment was ligated into pCDNA 3.1(-) plasmid vector
(Invitrogen, CA) under Xho1 and Bam H1 restriction enzyme sites, clones were selected
and verified by sequencing. The resultant plasmid was named MYH-208 WT (WT).
Splice site mutants and miR mutants were constructed by overlapping PCR using
following sets of primers and then ligating in pCDNA 3.1 (-) vector. 5’SS mutant was
constructed with primer 2085’SS F 5’-GAGGCCAACCGGGCTCCAG-3’ (forward) and
208 5’SS R 5’-CTGGAGCCCGGTTGGCCTC-3’ (reverse); U12 5’SS mutant with 208
U12 5’SS F primer 5’-GAGGCCAAGTATCCTTCAGATACCC-3’ (forward) and 208
U125’SS R 5’-GGGTATCTGAAGGATACTTGGCCTC-3’ (reverse); 208 U12BS
mutant with primer 208 U12BS F 5’-CACACACATCCTTAACCCTCACC-3’ (forward)
and

208

U12BS

R

5’-GGTGAGGGTTAAGGATGTGTGTG-3’
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(reverse).

Primers

used

for

lower

helix

mutant

CTGTGACGCCGCTCGAAAAGGCCCGGG-3’

(LH)

were

(forward)

208

and

LH

208

LH

F

5’-

R

5’-

CCCGGGCCTTTTCGAGCGGCGTCACAG-3’ (reverse). Primers used for upper helix
mutant (UH) were 208 UH F 5’-GGCCCGGGAATATCCTGATGCT-3’ (forward) and
208 UH R 5’-AGCATCAGGATATTCCCGGGCC-3’ (reverse). PCR-based site-directed
mutagenesis was performed using Change-IT multiple mutation site directed mutagenesis
kit (USB) to generate loop mutant (Loop) in WT background using 208 Loop primer 5’CCCGGGTTATACCACTACGAGTCGTATAAGACGAG-3’

and

MYH CC5/6GG

mutant was created in 208 U125’SS mutant background using 208 CC/GG primer 5’GAGGCCAAGTATGGTTCAG-3’.
For in vitro transcription, all the above mentioned mutants were PCR amplified
using forward primer with T7 promoter sequence, MYH T7BamH1 F 5’ATATGGATCCTAATACGACTCACTATAGGGGGAGCAGTACGAGGAGGAGA-3’
and MYH Xba1 reverse primer 5’-ACGGTCTAGACGTCCACCATCAAGTCCTCT-3’
and cloned between BamH1 and Xba1 sites of pUC19 vector.
Point mutants were made using Change-IT multiple mutation site directed
mutagenesis kit (USB) using the mentioned primers: 5’-CCAAGTAAGCTCC-3’ for
G3A; 5’-CCAAGTCAGCTCC-3’ for G3C; 5’- CAAGTGCGCTCCA-3’ for A4C;
5’-

CAAGTGGGCTCCA-3’

for

A4G;

5’-AAGTGAACTCCAG-3’

for

G5A;

5’- AAGTGACCTCCAG-3’ for G5C; 5’- AGTGAGGTCCAGA-3’ for C6G;
5’-

AGTGAGTTCCAGA-3’

for

C6T;

5’-GTGAGCGCCAGAT-3’ for T7G.
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5’-GTGAGCACCAGAT-3’

for

T7A;

p120 minigene construct (p120 WT) was a gift from Richard Padgett, Learner
Research Institute, Cleveland Clinic Foundation. It has a well characterized U-12
dependent intron (intron F). p120 CC5/6GG mutant was made by mutating CC5/6GG in
intron F of p120 WT. For p120-miR208 mutant, site-directed mutagenesis was performed
using Change-IT multiple mutation site directed mutagenesis kit (USB) to introduce
Pme1 and Not1 sites in the p120 WT construct in pCB6 vector using 5’GAGGAAGGCGGCCGCGAGAGG

G-3’

to

introduce

Not1

site

and

5’-

GAGAGGGGTTTAAACGCCTTAG-3’ primer to introduce Pme1 site. The DNA
fragment containing pre-miR330 was amplified by PCR from the WT plasmid using 5’GAATGCGGCCGCTGAACTCTGGCTGGCCCTGA-3’

(forward)

and

5’-

GCATGTTTAAACCACACAGGCTGATCGACGGT-3’ (reverse) and cloned into Pme1
and Not1 modified p120 WT. Site directed mutagenesis was performed using Change-IT
multiple mutation site directed mutagenesis kit (USB) and called p120 5’SS mutant with
primer 5’-GATGGAGCAGGATGAGTTTGCAGGGCAGAG-3’ and second mutant
called p120 CC5/6GG using 5’-TGGAGCAGGATATGGTTGCAGGGCAGAG-3’. U11
and U6atac suppressors cloned in pALTER expression vector was a gift from Richard
Padgett, Learner Research Institute, Cleveland Clinic Foundation.
All plasmids were transformed in DH5α competent cells, plated on Ampicillin
(Amp 100 mg/ml) containing Agar plates. Colonies were picked and grown overnight in
5ml Luria Broth (LB, Amresco, OH) containing 5 µl Amp (100 mg/ml) at 37 °C. Minipreps were done using Zyppy miniprep kit (Zymo Research, CA). Mutations were
confirmed by sequence analysis and then maxiprep was done using Plasmid Maxi Kit
(Qiagen, AL).
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2.2 CHO Cell Maintenance and Transfection
CHO cells were cultured in 10 ml complete CHO media containing DMEM-1x with
4.5 g/l glucose and L-glutamine (CCF, OH), P/S (CCF, OH), 5% FBS (Atlanta Biologicals,
GA), 1 mM L-proline (Sigma, MO) and 10 mM HEPES (SIGMA, MO). All cells were kept
in a humidified incubator at an atmosphere of 5% CO2 at 37 °C.
For transfection, a 100% confluent 100 mm plate was split at 1:8 ratio in 100 mm
plates using 10 ml complete CHO media. The cells were ~70 % confluent after 24 hrs and
morphologically healthy for transfection. Cells were transfected using 5 ml complete CHO
media containing 12 µl polybrene (10 mg/ml Sigma, MO) and 1.2 µg plasmid DNA per
plate. 9 µg pUC19 was used as carrier and to equalize amount of DNA being added. In wells
where both U11 suppressor plasmid and U6atac suppressor mutants were transfected
together, pUC19 vector was omitted. After 8 hrs, media from the wells was aspirated and
cells were treated with 5 ml of 30 % DMSO (in complete CHO media) and incubated at room
temperature for 5 minutes. Plates were washed with 5 ml complete CHO media and finally
replenished with 10 ml CHO media. Cells were cultured at 37 °C in a humidified 5 % CO2
incubator. The cells were harvested after 36 hours of incubation post-DMSO shock.

2.3 Total RNA Isolation
Total RNA isolation from cells growing in monolayer was done by TRIzol
Method, a modification of the method developed by Chomczynski,P. and Sacchi, N.
(1987). Briefly, the cells were lysed directly in culture dish by adding 1 ml TRIzol
(Invitrogen, CA) reagent to each well, transferred to an eppendorf and added 0.2 ml
Chloroform (Amresco, OH). Samples were centrifuged and aqueous phase was collected.
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RNA present in aqueous phase was precipitated and washed using Isopropanol (Amresco,
OH) and 70 % Ethanol (Amresco, OH) respectively. Pellet obtained finally was
resuspended in DEPC treated water and stored in -80 ºC till further use. The isolated
RNA was quantitated spectrophotometerically and absorbance was taken at 260 nm and
280 nm. Integrity of RNA was checked on denaturing 1% MOPS-Agarose gel.

2.4 Reverse Transcriptase- Polymerase Chain Reaction (RT-PCR)
Reverse transcription was performed using GeneAmp Thermostable rTth Reverse
Transcriptase RNA PCR Kit (Applied Biosystems, CA) using 0.5 µg total RNA per
reaction. A master mix was made as per manual but scaling down reaction volume to 10
µl.
For MYH-mir208 stem-loop and splice site mutants, RT was done using vector
specific RT primer 5’-CAACAGATGGCTGGCAACTA-3’ at 70 °C for 15 min in a
PTC-100 (Bio-Rad Laboratories, CA) thermal cycler. The reaction was stopped by
keeping tubes on ice for at least 5 min. PCR was performed using master mix specified in
the manual scaling down reaction to 40 µl using Exon Junction F primer 5’GAGGGCAAGGCGAAGAAC-3’. Amplification was done for 40 cycles consisting of
denaturation at 95 °C for 1 min, annealing/extension at 55 °C for 1.05 min and a final
extension at 68 °C for 7 minutes. RT for point mutants was performed using RT primer
according to user manual (Promega, WI).
For p120 minigene, RT was done using p120 mini-gene specific reverse primer E7-8-2 primer 5’-CTTCTAAGAACTCCACCAGCTCAGA-3’ at 70 °C for 15 min in a
PTC-100 (Bio-rad Laboratories, CA) thermal cycler. The reaction was stopped by
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incubating tubes on ice for at least 5 min. Then PCR was performed using master mix
specified in the manual scaling down reaction to 40 µl using E-5-6 primer
5’-GGCCCGGGAAGCTGCTGCTGGGATC-3’. Amplification was done for 40 cycles
with denaturation at 95 °C for 1 min, annealing/extension at 60 °C for 1.05 min and a
final extension at 68 °C for 7 minutes.

2.5 In vivo Splicing Phenotype Analysis for MYH6 miR-208
Nested PCR was performed using GoTaq PCR core system II (Promega, WI)
setting up a reaction of 25 µl according to manual provided. Primers used for
amplification were F2 5’- GGAGCAGTACGAGGAGGAGA-3’ (forward) and R2 5’CGTCCACCATCAAGTCCTCT-3’ (reverse). PCR was done using program “55”
involving denaturation at 95 °C for 3 min followed by 25 cycles of denaturation at 95 °C
for 1 min and annealing/extension at 60 °C for 1.05 min final extension at 68 °C for 7
min. The products were analyzed on 2 % Agarose-1X TBE gels.
Nested PCR was performed using GoTaq PCR core system II (Promega, WI) was
also preformed to check various spliced products with upstream and downstream exons.
Primers were used in different combinations as indicated. Primers used are indicated as F
for forward and R for reverse, F1: 5’-GGAAAAGGAGGCGCTAATCT-3’; F2: 5’-GG
AGCAGTACGAGGAGGAGA-3’; F3: 5’-GGCTGTTAATGCCAAGTGCT-3’; R1: 5’GCGTCCGTCTCATACTTGGT-3’; R2: 5’-CGTCCACCATCAAGTCCTCT-3’; R3:
5’-TCGTAGGCGTTCTTGAGCTT-3’. PCR amplification was done using PTC-100
(Bio-Rad, CA) thermal cycler. PCR program used was denaturation at 95 °C for 2 min,
followed by 36 cycles of denaturation at 95 °C for 1 min, annealing at 55 °C for 1 min,
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extension at 72 °C for 1 minute and a final extension at 72 °C for 5 min. PCR products
were checked on a 2 % Agarose gel.

2.6 In vivo Splicing Phenotype Analysis for p120 Minigene
Nested PCR was performed using Hi Fidelity PCR Kit (Roche, IN) setting up a
reaction of 25µl according to manual provided. Primers used for amplification were E6
long 5’- TTGTGCTGCCCCCTGCTGGGGAGATG-3’ (forward) and E7 long 5’TGAGCCCCAAAATCAGCAGAATTCC-3’

(reverse).

PCR

was

done

using

amplification program involving denaturation at 95 °C for 3 min followed by 25 cycles of
denaturation at 95 °C for 1 min and annealing/extension at 60 °C for 1.05 min, final
extension at 68 °C for 7 min. The products were analyzed on 3 % (2 % Agarose: 1 %
NuSieve) Agarose-1X TBE gels.

2.7 In vitro Transcription Assay
Reaction was set up at room temperature using maxiscript kit (Ambion, TX). A
50 µl reaction was set up and reagents were added in following order: 12.5 µl Nucleasefree water, 5 µl 10X Transcription Buffer (with DTT), 2.5 µl 10 mM ATP, 2.5 µl 1 mM
UTP, 2.5 µl 10 mM CTP, 2.5 µl 1 mM GTP, 2.5 µl 10 mM m7G(5’)ppp(5’)G cap analog
(Ambion, TX), 10 µl (2 µg) linearized DNA template, 5 µl [α-32P] UTP 800 Ci/mmol
(10 mCi/mL- MP Biomedicals, OH) and finally 5 µl T7 RNA Polymerase (10 U/µl). All
reactions were incubated at 37 °C for 2 hrs. Then, 2 µl RNase-free DNase I (2 U/µl) was
added to the reaction mixture to remove the DNA template, mixed thoroughly, and
incubated for 20 min at 37 °C. Gel loading Buffer II (Ambion, TX) was added to
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samples. Samples were loaded on pre-electrophoresed 8 M Urea 5% polyacrylamide gel.
Covered gel with saran wrap and exposed it to phosphor imager screen for about 1 min
and scanned and extracted the band. To elute RNA from gel, added 400 µl G50 buffer
(1.7 g Sodium Acetate, 0.5 ml 2 M Tris pH 7.5) to the band and eluted overnight on
rotator at 4 °C. Next day, collected supernatant in a fresh tube, 900 µl ethanol and 40 µg
glycogen (Roche, IN) were added and precipitated RNA at -20 °C overnight. Following
day, samples were spun at 13000 rpm 20 min and pellet obtained was resuspended in
nuclease-free H2O and store at -20 °C in a β-blocker.
Century Markers (Ambion, TX) were transcribed as per manual guidelines.
Briefly, reaction was set using 6 µL Nuclease-free water, 2 µL 10X Transcription Buffer
(with DTT), 1 µL 10 mM ATP, 1 µL 10 mM CTP, 5 µL 10 mM GTP, 1 µL 1 mM UTP, 1
µL 0.5 µg RNA Century Marker Template Set, 2 µL [α-32P] UTP 800 Ci/mmol (10
mCi/mL in aqueous solution) and 1 µL T7 RNA Polymerase (10 U/µL). Reaction mix
was incubated at 37°C for 1 hr and 1 µL RNase-free DNase I (2 U/µL) was added to the
reaction to remove the DNA templates, and incubated for an additional 15 min at 37°C.
The terminated transcription reaction was passed through a G-25 or G-50
chromatography column to remove unincorporated nucleotides. Counts per minute (cpm)
were recorded and sample was diluted to 2000 counts/µL.
Decade Markers (Ambion, TX) were transcribed as per manual guidelines.
Briefly, reaction mix was made in a nuclease-free tube using 1 µL Decade Marker RNA
(100 ng), 6 µL Nuclease-free water, 1 µL 10X Kinase Reaction Buffer, 1 µL [γ–32P]
ATP and 1 µL T4 Polynucleotide Kinase. Incubated at 37°C for 1 hr. Then 8 µL
Nuclease-free water and 2 µL 10X Cleavage Reagent were added. Reaction mix was
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further incubated at room temperature for 5 min. Then 20 µL Gel Loading Buffer II was
added to stop the reaction. The mixture was heated at 95°C for 5 min before loading on
the gel.

2.8 In vitro pre-mRNA Splicing in Cell-free Extracts
All reactions were set up on ice. Mix1 was made fresh every time and contained
25 µl ATP/Phosphocreatine/Cordycepin 5’ phosphate mix (60 µl 100mM ATP (Roche,
IN), 50 µl 0.5 mM Cordycepin 5’ phosphate (Sigma, MO), 100 mM Cordycepin
5’triphosphate- 15 µl and H2O- 375µl), 6 µl 0.5M Phosphocreatine and 49 µl H2O. To set
up a 25 µl reaction, added 8.0 µl Mix 1, 1.0 µl RNase inhibitor (SUPERase In- 20 U/µlAmbion, TX), 1 µl 25mM MgCl2, 4 µl nuclease-free H2O, 10 µl nuclear extract and
finally 1 µl substrate mRNA (P-32 labeled) in an eppendorf. If anti-U2 or anti-U12 2’Omethyl oligos (Dharmacon, CO) were used, the reactions were incubated at 30 °C for 15
minutes and then labeled-pre mRNA was added. To block U2 dependent splicing, 8 µM
anti-U2b oligo was used whose sequence is complementary to U2 nucleotides 27–49
(Dietrich et al, 1997). To block U12 dependent splicing 8uM anti-U2b oligo along with 5
µM anti-U12 oligo (Dharmacon, CO) was used whose sequence was complementary to
U12 nucleotides 11–28 (Dietrich et al, 1997). All reactions were incubated at 30 °C for
90 minutes in case of adeno and adeno-miR constructs and 3 hours for reactions
involving p120 and MYH. Then centrifuged and added 200 µl G50 buffer (1.7g Sodium
Acetate, 0.5 ml 2M Tris pH 7.5) followed by 5 µl Proteinase K (Roche, IN) and
incubated the reaction at 42 °C for 20 minutes. Then added 200 µl of phenol/ chloroform
(Ambion, TX), vortexed 3-4 times and centrifuged at 13000 rpm for 5 minutes at room
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temperature. Carefully collected the supernatant in another eppendorf and added 200 µl
chloroform (Amresco, OH), vortexed 3-4 times and centrifuged at 13000 rpm for 5
minutes at room temperature. Again collected supernatant in a new tube and added 40 µg
glycogen (Roche, IN) followed by 500 µl ethanol. Samples were kept at -20 °C overnight
for precipitation. Next day, centrifuged samples at 13000 rpm for 20 minutes at 4 °C and
pellet obtained was resuspended in 10 µl gel loading buffer II (Ambion, TX). Samples
were incubated at 95 °C for 2 minutes, immediately chilled on ice and loaded on heated
Urea-PAGE gel. Gel was run at 15-18W constant power. Gel was dried and exposed to
phosphor imager screen at least overnight.

2.9 Reverse Transcription and Quantitative Real-Time (qRT) PCR Analysis of
Mature miRNA Expression
First strand cDNA was synthesized from 100ng of total RNA using primers
specific for mature miR-208 and small nucleolar RNA 202 (sno202).The miRNAspecific primers were obtained from TaqMan MicroRNA Assays (Applied Biosystems
Foster City, CA). Reagents for cDNA synthesis were obtained from TaqMan MicroRNA
Reverse Transcription kit (Applied Biosystems, CA). For each sample, a 15µl reverse
transcription (RT) reaction was set up containing 10ng of total RNA, 1X RT buffer, 1mM
of dNTP mix, 50 units of MultiScribe reverse trancriptase, 3.8 units of RNase inhibitor
and 3µl of miRNA-specific RT primer. The reactions were incubated in a thermal cycler
(Bio-Rad PTC-100) at 16°C for 30 minutes, 42°C for 30 minutes, and 85°C for 5 minutes
and then held at 4°C. The ‘reverse transcriptase minus’ controls were also synthesized
under the same conditions. In order to quantify the mature miR-208 and sno202 in each
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sample, the cDNAs were amplified using TaqMan MicroRNA Assays together with the
TaqMan 2X Universal PCR Master Mix (Applied Biosystems, CA). Briefly, a 20µl
reaction was set up containing 1.33µl product from RT reaction, 1µl of 20X TaqMan
microRNA assay mix (mixture of miRNA-specific forward and reverse primers, and
miRNA-specific TaqMan MGB probe labeled with FAM fluorescent dye) and 10µl of
TaqMan 2X Universal PCR Master Mix. These reactions were dispensed into a 96-well
optical plate and the plate was positioned in 7500 Real-time PCR System (Applied
Biosystems) under the following conditions: 95°C for 10 minutes followed by 40 cycles
of 95°C for 15 seconds and 60°C for 1 minute. Three replicates were performed per RT
reaction together with the ‘reverse transcriptase minus’ and ‘no template’ controls.
Duplicate PCRs were performed for all the RNA sample. The mean Ct was determined
from the replicates. Sno202 expression was used as an invariant control. The relative
expression of each miRNA was calculated as 2-∆Ct where ∆Ct = Ct value of each miRNA
in a sample – Ct value of sno202 in that sample. All experiments were repeated with
three and all replicates provided similar results.
Statistical Analysis
The statistical analysis of expression levels of miR-208 and was performed using
the SPSS package. The index of expression of each miRNA was 2-∆Ct after normalization
to sno202 expression levels. A student t-test was applied to the samples. Expression
levels are considered significant if p < 0.5.
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CHAPTER III
RESULTS and DISCUSSION

3.1 Construction of MYH Minigene Reporter System
To study the events of pre-mRNA splicing and miRNA processing, a reporter
system that could experimentally enable us to study both processes was required. To
achieve this aim, a minigene reporter was constructed from Myosin Heavy Chain 6 gene
(MYH6). A 1764 base long fragment (Appendix 2) from exons 26 through 29 was PCR
amplified from human genomic DNA and cloned between the Xho1 and BamH1 sites of
pCDNA3.1 (-) under CMV promoter (Appendix 1). Hence, the reporter system consists
of exons 26 to 29, including introns 26, 27 and 28. Intron 27 of MYH6 gene encodes the
miRNA, miR-208. miR-208 has been implicated in regulating cardiac hypertrophy and
myocardial infarction (vanRooij et al, 2007; Callis et al, 2009).
A schematic of minigene reporter construct is represented in Figure 7. E 26 to
E29 correspond to the exons 26, 27, 28 and 29 from the MYH6 gene and I 26 to I 28
represent the introns 26, 27, 28 respectively. Forward primers designated as F1, F2 and
F3 are located in exons 26, 27 and 28 respectively and R1, R2 and R3 represents the
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reverse primers located in exons 27, 28 and 29 respectively (further details Chapter II and
Appendix).
F2

F1
E 26

I26

E 27

F3

miR-208

E 28

I27

R1

WT Splicing

R2

I28

E 29

R3

Figure 7: Structure of the minigene reporter construct and location of primers:
E represent the exons 26-29 and I represent the introns 26-28. Forward primers are
denoted by F and R represents reverse primers. miR-208 is encoded in the intron 27
of the minigene construct. Dashed lines show wild-type splicing junctions.

3.2 Expression of MYH in Mouse Tissues
miR-208 is encoded by intron 27 of MYH6 gene and is expressed specifically in
the heart and tracely in lungs (van Rooij et al, 2007; Callis et al, 2009). It was important
to know if MYH6 is expressed in
other tissues or is it tissue-specific as
miR-208. We performed RT-PCR on
MYH

RNA isolated from mouse organs,
heart, kidney, liver, brain and lungs.
GAPDH was used as an internal
control. Our data shows that MYH6
Figure 8: MYH6 expression in mouse
organs: RNA was isolated from mouse
tissues and RT-PCR analysis was done
using specific primers. Upper panel shows
results for MYH6 gene expression in
mouse tissues and lower panel shows
expression of GAPDH (internal control).
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expresses in lungs, heart and kidney
(Figure 8) if PCR amplification is
done for 30 cycles. Expression of
MYH6 gene was observed in brain as

well if the PCR cycles are increased from 30 to 40. However, MYH6 expression was not
detected in liver even at 40 cycles. Since the miR-208 expresses only in mouse heart and
tracely in lungs (van Rooij et al, 2007), its expression is tissue specific. Its expression
could also be regulated post-transcriptionally, however, any factors involved in miR-208
processing from intron 27 of MYH6 are not yet known. This experiment also suggested
us to choose a cell system not derived from heart, kidney, lungs or brain so that there is
no interference of endogenous MYH6.

3.3 Optimization of Transient Transfection Conditions

Figure 9: Optimization of transient
transfection conditions:
Minigene
construct was transfected at different
concentrations as indicated, RNA was
isolated 36 hrs post transfection and RT
using vector backbone primer and PCR
using F2 and R2 primers which flank miR208 containing exons was performed.

To study the events of splicing and miRNA processing it was necessary to
recapitulate the MYH6 splicing and miR-208 processing in an in vivo assayable system.
To achieve this objective, MYH6 minigene reporter system was constructed (as described
in Chapter II). MYH WT was transfected in HEK293T cells using lipofectamine at
concentrations of 0.4 µg, 0.8 µg, 1.0 µg and 1.2 µg per well of a 6-well plate along with
appropriate controls. Cells were harvested after 36 hours and RNA was isolated using
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Trizol. To specifically amplify exogenously transfected MYH6 minigene construct,

A
Figure 10: Optimization of
primers sets located on
MYH6 minigene construct:
PCR was performed with all
primers designed and in
Panel A spliced phenotypes
and primer sets used for
amplification are mentioned
on top. Panel B depicts
schematics
of
spliced
products obtained using all
combination sets of primers
in panel A along with their
sizes. Each box denotes an
exon. For example, lane 1 in
Panel A corresponds to
spliced phenotype obtained
using primers F1 and R1.
Schematic of spliced product
amplified shown in lane 1 is
represented in panel B,
product is spliced exons 26
and 27 and is 261 bp long.

B

reverse transcription was done using a vector backbone specific primer (RT primer) and
then PCR was done using F2 and R2 primers located on exons 27 and 28 respectively
(Figure 7). The PCR product was loaded on a 2% Agarose-1x TBE gel and compared the
splice variants (desired ~263 bp) with the 100 bp molecular weight ladder (Figure 9).
Some other non-specific products were observed at ~600 bp and ~1000 bp. When the
cDNA was cleaned up and purified to remove RT primer, none of the non-specific
products was observed. The best spliced phenotypes were observed at a concentration of
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1.2 µg transfected in HEK293T cells and this optimized concentration was used for
further transfections.
It was necessary to check if the in vivo splicing takes place from upstream and
downstream exons as well as the efficiency of MYH minigene reporter construct. RTPCR was performed using the vector specific primer and cDNA was cleaned using DNA
clean and concentrator kit. PCR amplification was done using appropriate sets of primers
as represented in Figure 10, panel A. If splicing occurs from the correct splice site
junctions, products of specific lengths shown in Figure 10, panel B are expected. Since
F1 primer is located on exon 26 and R1 primer is on exon 27, intron 26 will be spliced
out and the expected product size is 261 base pairs long (Figure 10, Panels A and B, lane
1). Similarly, F1 and R2 primers would yield a 418 bp long product by splicing of exons
26, 27 and 28 (Figure 10, Panel A and B, lane 2). Primers F1 and R3 are located in exons
26 and 29 respectively and would yield largest product of 590 bp by splicing of exons 26
to 29 (Figure 10, Panel A and B, lane 3). F2 and R3 primers would yield a product of
435 bp, by splicing exons 27 to 29 (Figure 10, Panel A and B, lane 4). Primers F3 and R3
are located on exons 28 and 29 respectively and yield a spliced product of 252 bp long
containing exons 28 and 29 (Figure 10, Panel A and B, lane 5). PCR products were
isolated from the gel and sequenced to identify the spliced junction sequences. The
sequencing results obtained showed that the PCR products spliced at correct splicing
junctions.
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3.4 In vivo Splicing Phenotypes of miRNA Stem-Loop Mutants
It has been proposed that RNA-RNA interactions or RNA-protein interactions are
involved in structure recognition and processing precursor miRNA to mature sequence.
Lower helix, upper helix and the terminal loop are the required structural regions for the
miRNA processing to occur (Kim and Kim, 2007). After optimization of the minigene
system, we wanted to answer specific question- whether miRNA sequence affects premRNA splicing or not. To answer this question we introduced mutations in the stem-loop
structure of hsa-miR208 (Figure 11 A).

WT

Lower Helix
Mutant

Upper Helix
Mutant

Loop
Mutant
Figure 11: Structure of predicted hsa-miR-208 stem loop: (A) correspond to
predicted stem-loop structure and sequence/regions of precursor miR-208. Sequence of
mature miR-208 is illustrated in green letters. (B)- (D) represent lower helix, upper
helix and loop mutants of hsa-miR-208. Regions marked with crosses in the mutants
indicate abolished base pairing interactions whereas extended helix is predicted to
form in loop mutant. Mutated bases are shown in bold letters.
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We introduced non-complementary mutations in the helical regions to disrupt the base
pairing interactions between 5’ and 3’ end of predicted miRNA stem-loop structure
(Figure 11, B and C). These mutants were called the lower helix (LH) or the upper helix
(UH) mutants. For the loop mutant, base pairing interactions were introduced at the
terminal loop region and hence formation of an extended helix is predicted (Figure 11 D).

Figure 12: In vivo splicing
patterns of miRNA mutants: UH,
LH and Loop mutants were
transfected with appropriate
controls. PCR was performed using
F2 and R2 primers. PCR products
were loaded on 2 % Agarose-1X
TBE gels.

All splice site mutants along with wild type minigene construct and appropriate controls
were transfected in CHO cells using polybrene and upon RNA isolation analyzed for
spliced phenotypes. Wild type (WT) spliced product is 263 bp long if splicing occurs at
correct splice junctions (Figure 12, lane 2). Upper helix (UH), lower helix (LH) and
Loop mutants did not have any effect on splicing and yield product similar to wild-type
(Figure 12, lanes 3, 4, 5). To verify if these mutants spliced from the wild type splice
junctions, PCR products were eluted from the gel and sequenced. The analysis of
sequencing data from the three miR-208 stem-loop mutants obtained showed that splice
junctions are same as that of the wild-type. This data from the miRNA stem-loop mutants
indicates that miRNA mutations do not affect splicing in vivo.
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3.5 In vitro Splicing Assay for Stem-Loop Mutants
There are advantages of using the in vitro system over the in vivo system. Firstly,
using an in vitro system all intermediate stages and products of splicing and miRNA
processing can be resolved on the same gel, on the other hand, using in vivo system only
the final spliced product can be identified. Secondly, one or more snRNAs can be
blocked at different time points to establish the role of snRNAs in splicing (and miRNA
processing). Splicing reaction kinetics can be studied and different complexes formed
during the process of splicing can be identified.
A 788 bp region containing exon 27 and exon 28 including the miR-208
harboring intron 27 was PCR amplified from miRNA stem-loop mutants as well as the
wild-type and cloned in pUC19 vector under T7 promoter. Plasmid DNA was linearized
with restriction enzyme, Xba1 and transcribed in vitro as described in Chapter 2. In vitro
splicing assay was performed in HeLa cell nuclear extracts as described earlier and in
vitro spliced phenotypes of MYH6 wild-type and miRNA stem-loop mutants were
analyzed on 8M Urea-8% PAGE gel. To compare the sizes of the products generated in
the assay, century (100 bp RNA ladder) and decade markers (10 bp RNA ladder) were
used (Figure 13, lanes 1 and 12 respectively) since products ranging from 70 bp (premiR-208) to 788 bp (pre-mRNA transcript) were expected. Adeno-viral mRNA with hsamiR-208 incorporated in intron was used as control to optimize in vitro splicing reaction
conditions. Both adeno-viral and MYH6 minigene constructs splice using major
spliceosomal pathway. Adenoviral construct containing miR-208 in intron was spliced in
vitro and spliced exons and precursor miR-208 (pre-miR-208) were observed (Figure 13,
lane 2), indicating that the nuclear extract is sufficient for in vitro splicing to occur.
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Spliced exons were not observed in adenoviral construct incubated with anti-U2 oligo
(Figure 13, lane 3). This showed that the anti-U2 oligo could block U2-dependent

Adeno

Figure 13: In vitro spliced phenotypes of stem loop mutants: Lane 1 shows
century marker, lane 12 shows decade marker, lanes 2 and 3 show in vitro spliced
adeno-miR construct. Lanes 4-5, 6-7, 8-9 and 10-11 show in vitro spliced MYH6
wild-type, UH, LH and Loop mutants respectively. Anti-U2 indicates samples where
anti-U2 oligo was added to block U2-dependent splicing. Drosha cleaved products
namely, miR-208 stem-loop, upstream exon to 5’ end of miR and from 3’ end of miR
to 3’exon were observed as indicated.
splicing (as its sequence is complementary to U2 nucleotides 27–49 (Dietrich et al,
1997). Interestingly, blocking splicing did not abolish miRNA processing upto the
40

precursor stage, though the level of pre-miR-208 observed was reduced. Wild-type MYH
construct appears to be splicing deficit, however precursor microRNA was observed
(Figure 13, lane 4). Interestingly, two pre-mRNA by-products were also observed
between 300 and 400 bp. These products appear to be Drosha cleaved products, i.e. the
region from starting of mRNA to 5’end of pre-miR-208 and 3’ end of pre-miR-208 to the
end of mRNA (Figure 13) and the length of these products should be 387 bp and 330 bp
(by analyzing the genomic sequence). However, the identity of these products has not
been experimentally proven yet. Wild type MYH construct along with anti-U2 oligo
showed reduced levels of the Drosha cleaved pre-mRNA products as well as the premiR-208 (lane 5). Interestingly, pre-miR-208 along with Drosha cleaved pre-mRNA was
also not detected in upper helix (UH) and the lower helix (LH) mutants, in the presence
or absence of anti-U2 oligo (Figure 13, lanes 6-9). In vitro spliced products of loop
mutant, with and without anti-U2 oligo are shown in lanes 10 and 11. This mutant is also
splicing deficient as the wild-type and hence spliced products were not observed,
however Drosha cleaved pre-mRNA products and pre-miRNA in low level were seen.
Recently, mRNA splicing and pre-miRNA processing have been detected in an in
vitro system with HeLa cell nuclear extract using the EML2 gene harboring miR-330
(Kataoka et al, 2009). The EML2 pre-mRNA was a good substrate for splicing as well as
miRNA processing in contrast to the MYH6 pre-mRNA. We also performed in vitro
splicing assay with a 900 bp long (including full exons 27 and 28) MYH6 pre-mRNA
substrate but observed similar results. We suspect that MYH6 gene might have some key
cis-regulating elements, upstream of exon 27 or downstream of exon 28, necessary for
MYH6 pre-mRNA to splice. Kataoka et al (2009) showed that pre-mRNA processing
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(cropping) occurs prior to pre-mRNA splicing and presence of miRNA in an intron slows
down the process of pre-mRNA splicing. Similar results were obtained with MYH6 premRNA where pre-miR-208 could be detected as early as 20 minutes but spliced mRNA
could not be detected even after 2 hours (Dietrich et al, unpublished).

3.6 In vivo Splicing Phenotypes of MYH6 Intron27 5’splice site Mutants
An intron has certain cis-acting elements which are required for splicing, namely,
5’splice site; branch point, adenosine and the consensus 3’splice site (Figure 14). These
cis-elements are required for binding to specific snRNAs and other factors associating
with snRNAs.

A

B

Figure 14: Consensus 5’splice site of U2-type intron and intron 27 of MYH6: The
Figure illustrates the cis-elements of intron required for splicing. Panel A correspond
to splice sites regions which are recognized by various snRNAs in a U2-dependent
intron. Panel B illustrates the cis-elements in intron 27 of MYH6 gene. WT 5’Splice
site is shown along with 5’SS mutant, U12-type 5’SS mutant sequences and U125’SS
CC/GG mutants. The letters in bold and underlined letters represent the mutated
nucleotides.
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Since, 5’ splice site binds to U1 and U6 snRNAs by Watson- Crick base pairing and these
RNA-RNA interactions are phylogenitically conserved and essential for splicing to occur,
we mutated the 5’ splice site of the intron 27 of the minigene reporter construct to
eliminate the wild type site (Figure 14, panel B). The 5’ splice site was a mutated to
consensus U12-type 5’ splice site (GUAUCCUU) and this mutant was called U125’SS
mut. Firstly, we wanted to know if this mutant would splice, since branch site and 3’
splice site were wild-type (i.e. U2-dependent) and secondly which spliceosomal
machinery (major or minor) would be used. Mutations were also introduced in the 5’
splice site such that it is neither U2-type nor U12-type and the mutant was called 5’SS
mut (CCGGGCUC). This mutant was constructed to completely eliminate the binding of
U1 and U6 snRNAs to the splice site junctions and identify if the mutant would splice.
The third mutation introduced was CC5/6GG mutation in the U125’SS mut to generate
the U125’SS CC/GG mutant (referred as CC/GG mutant). Using this mutant, we wanted
to know whether major or minor spliceosome, is splicing the MYH6 U125’SS mut.
Figure 15: In vivo splicing
patterns of MYH6 intron 27
5’ splice site mutants: 5’
splice site mutants were
transfected in mammalian
cells, RT-PCR was performed
and analyzed for splicing.
U12-type 5’SS mutant and
U12 5’SS CC5/6GG mutant
spliced products are similar to
wild-type. However 5’SS
mutant activates a cryptic
splicing event.

Since, it is known that wild-type splicing gets abolished and cryptic splicing is activated
if CC5/6GG is mutated in U12-dependent intron F of p120 gene. Using this construct in
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vivo suppression system, developed for U12-dependent (p120 gene) intron, could be
utilized (Hall and Padgett, 1996; Kolossova and Padgett, 1997; Incorvaia and Padgett,
1998). All splice site mutants were transfected in CHO cells using polybrene and upon
RNA isolation analyzed for spliced phenotypes. As expected, bands were not observed
seen in case of mock (negative) control. Wild type (WT) spliced product is 263 bp long
(Figure 15, lane 2). U125’SS mutant (lane 4) which had consensus U12-type 5’ splice
site showed phenotype similar to the wild type, suggesting either splicing takes place in
mutant utilizing the minor spliceosomal pathway or there is no effect of mutation on the
splicing. To answer this question, we utilized the CC5/6GG mutant (lane 5). RNA-RNA
interactions between the snRNAs and pre-mRNA are the basis of splicing and any
mutation in one of the interacting partners leads to inhibition of these interactions and
hence affects splicing. It has been shown that CC at positions 5 and 6 in a U12-dependent
intron are necessary for splicing to occur. If CC at 5 and 6 positions in a U12-dependent
intron are mutated, splicing does not take place. However, MYH6 U12 5’SS CC5/6GG
mutant spliced phenotype is similar to wild-type (Figure 15, lane 5). We co-transfected
suppressor U11 and U6atac snRNAs along with U125’ SS CC5/6GG mutant since,
suppressor snRNAs are known to restore splicing. U11 snRNA with a mutated GG6/7CC
and U6atac snRNA with mutated GG14/15CC are called suppressor snRNAs as they
restore the base pairing interactions with CC5/6GG in the U12 5’SS CC/GG mutant.
However, the results obtained were quite ambiguous and could not be reproduced. Upon
careful analysis of the wild-type genomic sequence and U12 5’SS CC/GG, we found that
both wild-type and CC/GG mutant have guanine (G) at the 5th position in intron 27. This
observation suggested that G at 5th position could be important in splicing intron 27. This
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observation was further supported by splicing phenotypes observed from in vivo spliced
point mutants, G5A and G5C (Figure 22, lanes 8 and 9) where splicing was completely
abolished (section 3.9).
The 5’SS mut which has 5’ splice site mutations (GTA 124/CCG) such that the
splice site is completely mutated for splicing, cryptic splicing was activated. Spliced
phenotype of 5’SS mut is smaller than the wild type (Figure 15, lane 3).

Figure 16: Affect of 5’ splice site mutation: The Figure illustrates the comparison of
WT (upper panel) and cryptic (lower panel) splicing of intron 27 of MTH6. Blue line
indicates that cryptic splice site is located in the exon 27. Sequence similarity of both
the sites recognized is shown in the lower panel. In the lower panel, region shown in
blue represents exon 27 and region in black illustrates intron 27.
The band was extracted from the gel, PCR product was eluted and its sequence was
analyzed. Since in this mutant, the intronic 5’ splice site GT was mutated to CC hence the
splice site no longer was U2 dependent, a cryptic 5’ splice site was utilized for the
splicing of the intron. Spliced sequence analysis showed that there is a 50 nucleotide shift
in 5’ splice site upstream of the normal splice site that produced smaller splice product
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(Figure 16). The upstream cryptic 5’ splice site is identical to the WT 5’ splice site which
is CCAA/GT.

3.7 In vitro Splicing Assay for Splice Site Mutants
To study the effect of 5’ splice site mutations on miRNA processing, we utilized
the in vitro splicing assay system. The splice site mutants were PCR amplified from exon
27 to exon 28 including intron 27 containing miRNA and cloned in pUC 19 vector under
T7 promoter. Plasmid DNA was linearized with Xba1 and the linear plasmid DNA was
transcribed in vitro in presence of α-P32 radio-labeled UTP. Then in vitro splicing assay
was performed in HeLa cell nuclear extracts as described in Chapter 2. Similar to miRNA
stem-loop mutants, splice site mutants also failed to splice in vitro and, pre-miR208 along
with Drosha cleaved mRNA products were detected (Figure 17). Anti U2 oligo to block
U2-dependent splicing and to block U12 dependent splicing both anti-U2 oligo and antiU12 oligo were added. As mentioned in section 2.8, sequence of anti-U2 oligo is
complementary to U2 snRNA nucleotides 27–49 (Dietrich et al, 1997) and sequence of
anti-U12 oligo is complementary to U12 snRNA nucleotides 11–28 (Dietrich et al, 1997).
We wanted to confirm if MYH6 U12 5’SS mutant construct splices using major or minor
spliceosomal machinery for splicing. But since the MYH6 substrates (wild-type as well
as the mutants) fail to splice in vitro system, we could not conclude if U125’SS mutant
splices using major or minor spliceosomal machinery. However, precursor miR-208
processed from wild type as well as 5’SS, U125’SS and U12 5’SS CC/GG mutants
(Figure 17). It appears that miRNA processing can occur even if splice products are not
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observed. MYH6 pre-mRNA is a good substrate for miRNA processing but a poor one
for splicing.

3.8 Quantitation of Mature miR-208 Expression in Splice Site and Stem-Loop
Mutants

A

B

PremiR208

Figure 17: In vitro spliced phenotypes of 5’ splice site mutants: Lane 1 and lane 9
shows century marker and decade markers, lanes 2-5 show in vitro spliced wild-type
MYH construct. Lanes 6-8 show 5’SS mutant. Panel B lanes 3-5 show U125’SS and
lanes 6-8 show U125’SS CC/GG mutant. Anti-U2 indicates lanes to which anti-U2
oligo was added and U12 indicates addition of anti-U12 oligo to block U2-dependent
and U12-dependent splicing respectively.
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miRNA processing is a compartmentalized process and first step takes place in
the nucleus where precursor miRNA is made and then second step occurs in cytoplasm
where precursor is processed to mature miRNA (Lee et al, 2002; Kim and Kim, 2007).
In vitro splicing assay gave us some insight about the precursor miR-208 since it takes
place in the nuclear extract. We detected only the spliced product by RT-PCR, mature
miRNA could be detected in vivo by quantitative RT-PCR (real-time PCR or qRT-PCR)
which is a sensitive and efficient method to detect small RNA species.
Mature miR-208 expression from stem-loop and the splice site mutants was
detected using qRT-PCR. The relative expression of miR-208 is plotted as 2-∆∆Ct after
normalizing to snoRNA202 and then to WT. miR-208 expression in case of loop mutant
is expressed approximately 30

2-∆∆Ct

Figure 18: Quantitative
RT-PCR expression of
mature miR-208 from
MYH6 stem-loop and 5’
splice site mutants: The
Figure shows relative
expression of miR-208
expressed from various
mutants. Relative
expression is plotted as 2∆∆Ct
after normalizing to
sno202 expression levels
and then to WT mir-208
levels.

folds as compared to the wild
CC/GG

type (Figure 18). miR-208

expression at such a high level from loop mutant could be due to any changes in the
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secondary structure of miRNA or change in sequence at the terminal loop region could
have caused such an increase. It is thought that the terminal loop region plays a very
important role in miRNA processing (Kim and Kim, 2007). Figure 19 represents same
graph as Figure 18 without comparing loop mutant as it becomes difficult to compare
expression profile of miR-208 from other mutants with high level if expression from the
loop mutant. The relative expression of miR-208 in all the mutants namely 5’SS, U12
5’SS, U12 5’SS CC5/6GG (referred as MYH CC/GG in Figure 18 and 19) and UH
mutant is reduced as compared to the wild type. All these mutants besides 5’SS mut show
similar splicing phenotypes as the wild-type (Figures 13 and 15).
This indicated mutations in the 5’ splice site of the intron affect miRNA

2-∆∆Ct

processing and also mutating the stem-loop structure of miRNA affect miRNA-

CC/GG

Figure 19: Quantitative RT-PCR expression of miR-208 from MYH6 stem-loop
and 5’ splice site mutants: The figure shows relative expression of miR-208
expressed from various mutant constructs. Relative expression is plotted as 2-∆∆Ct after
normalizing to snoRNA202 expression levels and then to WT.
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processing as well. Interestingly, U12 5’SS CC5/6GG almost failed to express miR-208
showing that CC5/6 are important for miR-208 processing. These results suggest there is
some interplay between the splice site and miRNA processing.

3.9 In vivo Splicing Phenotypes of Point Mutants
Pictogram is a pictorial representation of analysis of nucleotides at a particular
position in a DNA sequence. A pictogram representing the 5’ splice site sequence content
of miRNA harboring introns was designed (Figure 20). Size of nucleotide at a position is

Figure 20: Pictogram representing 5’ splice site of 15 miRNA coding introns: -1
to -17 represent the sequence at exonic splice site junction and 1 to 17 represent the
MYH CC/GG
bases in the intron and -1 to -17 represent the 5’ exon. Bigger size of base at a
position corresponds to higher conservation.
proportional to its conservation for example; A is more conserved at position 3 than G.
Based on this splicing sequence content, point mutations in intron 27 of minigene were
made. The 5’ splice site of intron 27 of the myosin heavy chain was mutated at positions
3 through 7 (Figure 21). If the 5’ splice site sequence of MYH intron 27 is compared with
that of pictogram, considerable similarities and dissimilarities are seen. G and T at
positions 1 and 2 respectively are completely conserved, indicating their evolutionary
importance and could possibly have a role in pre-mRNA splicing and miRNA processing.
Purines are largely present at positions 3-7. AAG at positions 3-5 are conserved as well,
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however GCA can be present in some cases (Figure 20). Positions 6 and 7 are quite
degenerate with lack of C and T at 6th and 7th position respectively.
As mentioned before, the 5’ splice site of MYH intron 27 was mutated based on
sequence conservation of miRNA coding introns. Mutant G3A had a mutation from G to
A at position 3 since A is more dominant than G at the position (Figure 21). At position
4, base A is present in majority of introns studied, although C is found as well; intron 27
also has A at 4 position so we mutated A at 4 position to C and called it A4C mutant and
in A4G mutant mutated A at 4 position to G keeping in mind that G is not present in
miRNA coding introns. Similarly G5A and G5C mutants were made for 5th position
where A is rarely present and C is not present as per pictogram. Pyrimidine C is not
present at 6th position in the pictogram, however it is present in MYH intron 27 so C6G
and C6T mutants were made for position 6. For the 7th position T7A and T7G mutants
were made by comparing intron 27 with the pictogram.

Figure 21: Intron 27 of MYH showing 5’ splice site point mutations: Upstream and
downstream exons are shown in orange boxes and miR-208 is shown in the intron.
Numbers 1-8 represent the positions of bases in the intron. Introduced mutations are
indicated by the dashed lines. For example, G at position 5 is mutated to A and mutant
is called G5A, another mutant G5C has a mutation from G to C at 5th position.
All point mutants were transfected in CHO cells using polybrene, RNA was
isolated after 36 hours and analyzed for spliced phenotypes. As expected, spliced and
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unspliced product bands were not found in negative controls (Figure 22, lanes 2 and 3).

A

B

Figure 22: In vivo splicing patterns of 5’ splice site point mutants: Point mutants
were transfected in mammalian cells, RT-PCR was performed using the F2 and R2
primers. Panel A illustrates the affect of point mutations at positions 3 through 7 in the
5’ splice site of intron 27 on splicing in vivo. Panel B depicts quantitation of relative
splicing among the point mutants.
Both unspliced and spliced products were observed in the wild type as well as in the
mutants. The wild-type spliced product is 263 bp long (Figure 22, lane 4). G3A mutant
appears to splices better than the wild-type (lane 5).
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This could be due to the fact that in adenosine is a preferred base at position 3 than G
(though it is present in some introns). Splicing goes down in case of 4’ position mutants
(lanes 6 and 7) since adenosine is again a preferred base at the 4th position and C is seen
in some introns coding miRNA. If we mutate A to C, splicing decreases but if A is
mutated to G a further reduction in splicing is seen. In case of 5’ position where guanine
is the preferred nucleotide and was mutated to A (lane 8) and C (lane 9) negligible
splicing was seen, indicating the importance of G at 5th position. As shown in the
pictogram, positions 6 and 7 are quite degenerate and flexible for nucleotides, mutating C
and T at 6th and 7th position respectively did not abolish splicing. However, splicing with
6th position mutants was as good as the wild-type (Figure 22, lanes 10 and 11). Splicing
was little reduced as compared to the wild-type in the 7th position mutants as nucleotides
A and G are also found at this position. The spliced and unspliced products obtained with
the 4th and 5th position mutants (A4C, A4G, G5A and G5C) do not correspond to the total
spliced and unspliced product quantity as the wild-type and other mutants. It is possible
that splice site junction recognized by the spliceosome is upstream or downstream of the
F2 and R2 primers and therefore, could not be amplified and detected. There is another
possibility that the region of exons 27 and 28 was skipped during splicing and hence
spliced and unspliced products were not observed.

3.10 Quantitation of Mature miR-208 Expression in Point Mutants
qRT-PCR was performed on the same RNA that was used for in vivo splicing
phenotype analysis for the 5’splice site point mutants so that miRNA expression could be
compared with relative splicing. The relative expression of mature miR-208 normalized
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to snoRNA202 was calculated and a graph was plotted (Figure 23). miR-208 expression
reduces in G3A mutant as compared to the wild type. The reduction in miRNA

Figure 23: Quantitative RT-PCR expression of miR-208 in point mutants: The
figure shows relative expression of miR-208 plotted as 2-∆∆Ct after normalizing to
snoRNA202 expression levels and then to miR-208 levels from the wild-type.
expression is more significant in the A4C, A4G and G5A mutants. This indicated adenine
and guanine at 4th and 5th positions is not only important for splicing (Figure 22) but also
for miRNA processing. miR-208 levels from C6G, C6T and T7A mutants were higher
than wild type levels indicating these mutations in the splice site enhanced the processing
of miRNA. The level of relative splicing in 6th and 7th position mutants is also better than
wild type suggesting these mutations not only increase splicing but also miRNA
processing. qRT-PCR and the in vivo splicing analysis using RT-PCR show that presence
of some nucleotides at a certain position is more favorable for pre-mRNA splicing or premiRNA processing to take place.

54

3.11 In vivo Splicing Phenotypes for U12-dependent miRNA System
p120 gene or human nucleolar proliferative antigen gene has a well identified
U12-dependent intron, intron F, which has been characterized for both in vivo as well as
in vitro splicing. Since no microRNA is known to exist in an U12-dependent intron, we
were interested if U12-dependent intron would be compatible with miRNA processing if
it is introduced in the intron upstream of branch site. Also we wanted to address if
splicing of a U12-dependent intron would be affected by presence of miRNA.
We introduced a hsa-miR-208 encoding 137 bp fragment from intron 27 of

Figure 24: Intron F of p120 minigene showing introduced miR-208 and
mutations: miR is represented by the stem-loop structure between 38 and 175
nucleotides, branch point Adenosine is marked at 214th base. Mutated bases are
shown in bolds.
MYH6 in the intron F of p120 minigene reporter construct (Figure 24). We also mutated
the 5’ splice site region in intron F to identify the affects of these mutations and presence
of miRNA on splicing and miRNA processing. It has been shown that if CC at 5th and 6th
position in intron F of p120 minigene are mutated to GG a cryptic splicing event is
activated as shown in Figure 25 (panel A) (Incorvaia and Padgett, 1998). It has also been
shown that if U11 snRNA GG6/7CC and U6atac GG14/15CC are cotransfected with
p120 intron F CC5/6GG mutations, it restores splicing as wild type. p120 minigene
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construct and its mutants along with appropriate controls were transfected in CHO cells,
isolated RNA and performed RT-PCR and the results are shown (Figure 25, panel B).
Negative controls as expected did not show any bands (Figure 25, Panel B, lanes 2 and
3). In vivo spliced p120 wild type showed spliced, cryptic and unspliced bands (Figure
25, Panel B, lane 4). Lane 5 shows spliced variants for p120 CC5/6GG mutant where a
cryptic splicing event takes place and hence spliced band was not observed. However, an
increased level of unspliced product was also observed.
Splicing phenotypes for p120 miR-208 mutant are shown in lane 6 and in this

Figure 25: In vivo splicing patterns of p120 mutants: p120 mutants and wild-type
was transfected in mammalian cells and RT-PCR analysis was done for spliced
phenotypes. Panel A illustrates the site of miR-208 introduction and sites where
cryptic or wild-type splicing takes place. Panel B shows splicing phenotypes of the
p120 mutants. Marked with arrows are spliced, cryptic spliced and unspliced bands.
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case cryptic splicing does not take place and only spliced or unspliced products were
detected. Unspliced product was only observed upon the in vivo splicing analysis of p120
miR-208 5’SS and p120 miR-208 CC5/6GG mutants (Figure 25, panel B, lanes 7 and 8
respectively). Introduction of the 5’ splice site mutations and/or introduction of miRNA
in the intron completely abolished the splicing event. Co-transfection of U11 snRNA
GG6/7CC and U6atac GG14/15CC snRNA with the p120 miR-208 CC5/6GG mutant
(lane9) also did not rescue the splicing defect (as it does in p120 wild type, Incorvaia and
Padgett, 1998).

3.12 Quantitation of Mature miR-208 Expression in U12-dependent miRNA System
qRT-PCR was performed on the same RNA that was used for in vivo splicing

2-∆∆Ct

phenotype analysis for the p120 miR-208 wild type and splice site mutants so that

Figure 26: Quantitative RT-PCR expression of miR-208 in p120 system: The
figure shows relative expression of miR-208 expressed from p120 minigene system,
plotted as 2-∆∆Ct after normalizing to sno202 expression levels and then to miR-208
levels from the p120miR construct.
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miRNA expression could be compared with relative splicing. The relative miR-208
expression normalized to sno202 and then to p120 miR is plotted (Figure 26). Since,
microRNA is not known to exist in a U12-dependent intron; we were interested in finding
if microRNA would be processed from U12-dependent intron. miR-208 expression for
p120 miR208 CC5/6GG mutant is approximately 11 folds the level of p120 miR208 wild
type and it is about 10 folds for p120 miR208 5’ SS mutant (Figure 26). But if these
results are compared with the in vivo splicing results (Figure 25), we do not observe a
positive co-relation between the two processes as splicing is completely abolished in
these mutants; however, miRNA processing is better than the wild type. It apparently
appears that Drosha (microprocessor) is actively processing the miRNA to its precursor
but splicing is not taking place. It could be due to the fact that the splicing machinery and
miRNA processing machinery cannot act together in a U12-dependent intron. If this is
the case then which component of spliceosome is of utmost importance and what does
microprocessor and spliceosome share in common remains unanswered.
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CHAPTER IV
CONCLUSIONS AND FUTURE DIRECTIONS

4.1 Conclusions
Using the MYH6 minigene construct, we were able to utilize CHO cell-based
transient transfection system to study pre-mRNA splicing and miRNA processing. miR208 expresses from the intron 27 of MYH6 gene, in the heart and tracely in lungs. Our
results show that MYH 6 expresses in heart, kidney, lung, sparsely in brain but none in
liver, indicating miR-208 expression is tissue-specific or regulated post-transcriptionally
as MYH6 expresses in kidneys and lungs where miR-208 does not express. There could
be some additional factors that are required for miR-208 expression, which are present in
heart and lungs, aiding in its efficient processing. Since, miR-208 is located intronically,
effect of miR sequence (and structure) on pre-mRNA splicing was studied. Mutations in
the predicted stem-loop structure of miR-208 do not affect pre-mRNA splicing. But since
the mutations were introduced in the predicted stem-loop regions of miR-208, namely,
lower helix, upper helix and loop regions, the effect on miR expression level was
expected. The in vitro splicing assay in cell-free extract using the stem loop mutants
showed that the MYH6 pre-mRNA is a poor substrate for in vitro splicing but gave some
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insight on miRNA processing. Pre-miR-208 was detected in the wild-type and loop
mutants but it was not detected in upper helix and lower helix mutants suggesting
importance of the helical regions in miRNA processing. We performed the quantitative
RT-PCR to detect the expression levels of mature miR-208 from these mutants.
Expression of miR-208 from loop mutant is approximately 30 folds compared to the wild
type, on the other hand, its expression from upper helix mutant reduced 5 folds. Since,
miR-208 is intronically located, splice site sequences could also influence miRNA
processing so the 5’ splice site region of intron 27 (intron harboring miR-208) was
mutated. In vivo splicing showed that the U12 5’SS mutant and CC5/6GG mutant splice
similar to the wild-type but 5’SS mutant activated a cryptic splicing event. DNA
sequencing on the PCR product revealed that splicing takes place from a site located in
the exon 27. The sequence is located 50 nucleotides upstream of wild-type site and is
identical to the wild-type sequence. Level of mature miR-208 expression was detected by
qRT-PCR studies and was reduced as compared to the wild-type levels. miR-208
expression from 5’SS was reduced approximately 5 folds as compared to the wild-type
and negligible from the CC5/6GG mutant. To study how flexible and permissive is the 5’
splice site to allow miRNA processing and splicing to occur, point mutations were
introduced in 5’ splice site of intron 27. G3A mutant splices better than the wild-type and
miR-208 levels are comparable to the wild type. This could be due to the fact that in
adenosine is a preferred base at position 3 than G (though it is present in some introns).
Splicing goes down in case of 4’ position mutants (A4C and A4G) since adenosine is
again a preferred base at the 4th position and C is seen in some introns coding miRNA. If
A is mutated to C, splicing decreases but if A is mutated to G a further reduction in
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splicing is seen. About 2 folds reduction in miR-208 expression was observed with both
A4C and A4G mutants. In case of 5’ position where guanine is the preferred nucleotide
and was mutated to A or C, negligible splicing was detected, indicating the importance of
G at 5th position. About 2 folds decrease in miR-208 expression was detected fir G5A
mutant; however, level of expression for G5C mutant was comparable to the wild-type.
Positions 6 and 7 are quite degenerate and flexible for nucleotides, mutating C and T at
6th and 7th position respectively did not abolish splicing. However, splicing with 6th
position mutants (C6G and C6T) was as good as the wild-type but miR-208 expression
from both mutants was better than the wild type. Splicing was little reduced as compared
to the wild-type in the 7th position mutants since nucleotides A and G are also found at
this position in some miRNA containing introns. T7A expressed miR-208 about 1.7 folds
compared to the wild-type, on the other hand, 2 folds decrease was observed in T7G
mutant. It appears that G, A and G are required at 3rd, 4th and 5th positions respectively for
both pre-mRNA splicing and miR-208 processing to occur. Till now, miRNAs have been
detected in U2-dependent introns but none in U12-dependent introns. After introduction
of miR-208 in intron F (U12-dependent) of p120 minigene and mutating 5’ splice site of
intron F, in vivo splicing and qRT-PCR analysis was done. We observed that p120 with
miR-208 splices but its mutants (5’SS and CC5/6GG) failed to splice. However, miR-208
expression was 3 and 4 folds in CC5/6GG and 5’SS mutants respectively as compared to
the p120 with miR-208. We did not observe a positive co-relation between the two
processes as splicing is completely abolished in these mutants; however, miRNA
processing is better than the wild type. It appears that Drosha (microprocessor) is actively
processing the miRNA but splicing is not taking place if miR-208 is present in minor
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class intron in case of the p120 miR-208 CC5/6GG and p120 miR-208 5’SS mutants. It
could be due to the fact that the splicing machinery and miRNA processing machinery
cannot act together in U12-dependent intron where miR-208 has been incorporated and 5’
splice site has been mutated.

4.2 Future Directions
We want to establish if miRNA processing and splicing in both, U2-dependent
or U12-dependent intron are inter-linked. It can be proven by the in vitro splicing assay in
cell-free extracts. In vitro splicing assay also aids to determine various intermediates and
hence understand basic mechanism coupling the two processes. Since the MYH6
substrate used before was splicing deficient, a new construct which would enable
studying miRNA processing and pre-mRNA splicing is required. It can be achieved by
introduction of certain cis-element sequences essential for splicing. We have detected the
mature miR-208 expression levels in wild type as well as the mutants, but precursor miR208 levels can also be detected using qRT-PCR. We want to develop an in vivo
suppression assay system for intron 27 of MYH6 minigene. We would utilize the in vivo
suppression assay system for intron F of p120 minigene and suppress splicing in
CC5/6GG mutant using the U11 and U6atac snRNA suppressors. Finally, we would
identify the protein/factor involved if pre-mRNA splicing and miRNA processing are
coupled.
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APPENDIX

Appendix 1: Vector Map pCDNA3.1- : It has ampicillin (Amp)
as selection marker for E.Coli and Neomycin as selection in
mammalian cells. It has a human cytomegalovirus (CMV)
promoter. The multiple cloning site showing restriction enzyme
sites is represented. Genomic region from exon 26 to 29 including
introns from MYH 6 gene was cloned between Xba1 and Bam H1
sites.
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GAGAGTTGGCCCGGCAGCTAGAGGAAAAGGAGGCGCTAATCTCGCAGCTGACCC
GGGGGAAGCTCTCTTATACCCAGCAAATGGAGGACCTCAAAAGGCAGCTGGAGG
AGGAGGGCAAGgtgaggcccagtggggagggtgggcaggcttgatggcagccct
ggggcaattcatctcagtgccagaaatggagcctggagctggaaagagtcctct
gcaagggaaagaccctccagtctaggttctgccctgcagctaagcgtcatttaa
tgcctcttttcttattcgtaaggggatggggtgagcagactgggaaactcctca
aacagtgaggtgccacatcagcccacatggtgaataaggctgggcttggttgaa
gtactacataagaagagaatctagagaatggggcacagggagtccctcccacct
cctggtgcccccccccctccccagGCGAAGAACGCCCTGGCCCATGCACTGCAG
TCGGCCCGGCATGACTGCGACCTGCTGCGGGAGCAGTACGAGGAGGAGACAGAG
GCCAAGGCCGAGCTGCAGCGCGTCCTGTCCAAGGCCAACTCGGAGGTGGCCCAG
TGGAGGACCAAGTATGAGACGGACGCCATTCAGCGGACTGAGGAGCTCGAAGAG
GCCAAgtgagctccagatacccccttaacctgactctcagagaggaaggggcga
gaggacctggggtggggacaggcaaagtggtcatgagacggaagtggaagagac
aggaggaactcggagggcaacagaagtgcttggaagaaagcctgaactctttgc
tctgtgaactctggctggccctgacccacttcctgtgacgggcgagcttttggc
ccgggttatacctgatgctcacgtataagacgagcaaaaagcttgttggtcaga
ggagctaccgtcgatcagcctgtgtggggggtgagggcagggggcactgacacc
cagatgccactgcaggtagggaggacgcctgggcagcccgtgctggcggactct
gttccaggcatgagcaggctcagctcctgctaggctggacttacggtgtctcaa
ggagatatagggagggggtggaaggaggtccacccaaggctccagtgttgccca
gtagagtcacacacacaccctccaccctcacctgggcagAAAGAAGCTGGCCCA
GCGGCTGCAGGATGCCGAGGAGGCCGTGGAGGCTGTTAATGCCAAGTGCTCCTC
ACTGGAGAAGACCAAGCACCGGCTACAGAATGAGATAGAGGACTTGATGGTGGA
CGTAGAGCGCTCCAATGCTGCTGCTGCAGCCCTGGACAAGAAGCAGAGAAACTT
TGACAAGgtggaccatgggcgggggccgcagccagcatgcagggcaagggggca
tgaggggttcagtgagaggccaaaggcaacctccttggaggtggaggaggaggg
ctaagcccaggctcgggaccagggacagatcttggacatgcggctgaggctggg
ggctggggcactgggaagcaggagggctggggagctaaggctggggggctgaag
agtgagccttgtccccgggcagATCCTGGCCGAGTGGAAGCAGAAGTATGAGGA
GTCGCAGTCTGAGCTGGAGTCCTCACAGAAGGAGGCTCGCTCCCTCAGCACAGA
GCTCTTCAAGCTCAAGAACGCCTACGAGGAGTCCCTGGAGCACCTAGAGACCTT
CAAGCGGGAGAACAAGAACCTTCAGG
Appendix 2: Sequence of MYH 6: The cloned genomic sequence of human
Myosin Heavy Chain 6 gene. Exons are shown in bold and capital letters.
Intronic sequences (intron 26-28) are shown in small letters. hsa-miR-208 is
bolded in the intronic region and mature miRNA is underlined.
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Appendix 3: Sequences of Primers: All primers are in 5’ to 3’ direction.

1.

MYH Xho F: GCCTCGAGGAGAGTTGGCCCGGCAG

2.

MYH BamH1 R: ACGGGATCCCCTGAAGGTTCTTGTTC

3.

F1: GGAAAAGGAGGCGCTAATCT

4.

R1: GCGTCCGTCTCATACTTGGT

5.

F2: GGAGCAGTACGAGGAGGAGA

6.

R2: CGTCCACCATCAAGTCCTCT

7.

F3: GGCTGTTAATGCCAAGTGCT

8.

R3: TCGTAGGCGTTCTTGAGCTT

9.

Exon Junction F: GAGGGCAAGGCGAAGAAC

10.

Exon Junction R: GGCCAGGATCTTGTCAAAGT

11.

208 5’SS F: GAGGCCAACCGGGCTCCAG

12.

208 5’SS R: CTGGAGCCCGGTTGGCCTC

13.

208 U12 5’SS F: GAGGCCAAGTATCCTTCAGATACCC

14.

208 U125’SS R: GGGTATCTGAAGGATACTTGGCCTC

15.

208 U12BS F: CACACACATCCTTAACCCTCACC

16.

208 U12BS R: GGTGAGGGTTAAGGATGTGTGTG

17.

208 LH F: CTGTGACGCCGCTCGAAAAGGCCCGGG

18.

208 LH R: CCCGGGCCTTTTCGAGCGGCGTCACAG

19.

208 UH F: GGCCCGGGAATATCCTGATGCT

20.

208 UH R: AGCATCAGGATATTCCCGGGCC

21.

Loop mutant: 5’ CCCGGGTTATACCACTACGAGTCGTATAAGACGAG
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22.

208 CC/GG primer: GAGGCCAAGTATGGTTCAG

23.

MYH T7BamH1:

ATATGGATCCTAATACGACTCACTATAGGGGGAGCAGTACGAGGAGGAGA
24.

MYH Xba1 reverse: ACGGTCTAGACGTCCACCATCAAGTCCTCT

25.

GAPDH Forward: GGAGAAACCTGCCAAGTATGATG

26.

GAPDH Reverse: TGAAGTCGCAGGAGACAACCT

27.

P120_Not repair: GAGGAAGGCGGCCGCGAGAGGG

28.

P120_Pme Repair: GAGAGGGGTTTAAACGCCTTAG

29.

Mir208 pri not Forward: GAATGCGGCCGCTGAACTCTGGCTGGCCCTGA

30.

Mir208 pri pme Reverse: GCATGTTTAAACCACACAGGCTGATCGACGGT

31.

P120 5’SS mut: GATGGAGCAGGATGAGTTTGCAGGGCAGAG

32.

P120 CC5/6GG mut: TGGAGCAGGATATGGTTGCAGGGCAGAG

33.

G3A: CCAAGTAAGCTCC

34.

G3C: CCAAGTCAGCTCC

35.

A4C: CAAGTGCGCTCCA

36.

A4G: CAAGTGGGCTCCA

37.

G5A: AAGTGAACTCCAG

38.

G5C: AAGTGACCTCCAG

39.

C6G: AGTGAGGTCCAGA

40.

C6T: AGTGAGTTCCAGA

41.

T7A: GTGAGCACCAGAT

42.

T7G: GTGAGCGCCAGAT
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